drugset
drugset / Trial / NCT04608110

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

NCT04608110 ↗

Phase 1 Recruiting 40 enrolled Taiho Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to identify the doses of the oral azacitidine formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2

Timeline

Start
2020-10-30
Primary completion
2025-12
Completion
2026-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Oral
Subject Cedazuridine Small molecule — Oral

Indications

myelodysplastic syndrome